Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from bioAffinity Technologies, Inc. ( (BIAF) ) is now available.
On February 17, 2026, bioAffinity Technologies reported a real-world clinical case study in which its CyPath® Lung test aided management of a 59-year-old high-risk smoker with multiple small pulmonary nodules categorized as probably benign. The noninvasive test returned a result of unlikely malignancy, reinforcing guideline-consistent CT surveillance and helping reduce patient anxiety while improving physician confidence in deferring invasive procedures.
The company highlighted that CyPath® Lung, which has shown 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in small nodules, can serve as an adjunctive tool to stratify risk in indeterminate cases. The case supports CyPath® Lung’s clinical utility in evidence-based surveillance decisions for high-risk smokers, potentially strengthening the test’s positioning in the lung cancer diagnostics market and offering added assurance to clinicians and patients managing benign nodules.
The most recent analyst rating on (BIAF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, large losses, very negative ROE, and negative operating cash flow). Technicals also lean bearish (below moving averages and negative MACD). Positive corporate updates (CAP accreditation and CyPath® Lung traction) and the lack of a meaningful P/E due to losses provide only limited offset.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage lung cancer and other lung diseases, as well as broad-spectrum cancer treatments. Its lead product, CyPath® Lung, is a Laboratory Developed Test marketed through subsidiary Precision Pathology Laboratory Services for high-risk patients with small, indeterminate lung nodules.
Average Trading Volume: 103,232
Technical Sentiment Signal: Sell
Current Market Cap: $4.68M
For an in-depth examination of BIAF stock, go to TipRanks’ Overview page.